Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Abdulmalek Sadah

Psychiatry Novi, MI Medical Doctor

NPI 1942410667 CMS profile 133154

43000 W 9 Mile Rd Ste 207, Novi, MI 48375

Open in the dashboard

General payments

$44,362

75 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Abdulmalek Sadah of Novi, MI is reported in the CMS Open Payments database as having received $44,362 across 75 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $131 6
2022 General $5,849 12
2021 General $13,346 16
2020 General $7,701 14
2019 General $17,335 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Abdulmalek Sadah
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Abdulmalek Sadah were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Abdulmalek Sadah Psychiatry median Middle half National median
2019 $17,335 $184 $59–$605 $163
2020 $7,701 $119 $36–$372 $114
2021 $13,346 $143 $43–$576 $132
2022 $5,849 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $131 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Alkermes, Inc. $43,680 44 payments
  2. Janssen Pharmaceuticals, Inc $239 6 payments
  3. Otsuka America Pharmaceutical, Inc. $164 9 payments
  4. AbbVie, Inc. $122 7 payments
  5. Lundbeck LLC $37 2 payments
  6. Allergan Inc. $30 2 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $30 2 payments
  8. Indivior Inc. $28 1 payment
  9. Vanda Pharmaceuticals Inc. $20 1 payment
  10. Teva Pharmaceuticals USA, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $41,300 16 payments
  2. Food and Beverage $2,360 53 payments
  3. Travel and Lodging $689 5 payments
  4. Education $13 1 payment
Products named General payments · program years 2019–2024
  1. ARISTADA Cns $43,659 42 payments
  2. ARISTADA Cns $43,659 42 payments
  3. ARISTADA INITIO $43,659 42 payments
  4. ARISTADA Cns $43,614 40 payments
  5. ARISTADA Cns $43,614 40 payments
  6. SPRAVATO $174 4 payments
  7. VRAYLAR $122 7 payments
  8. REXULTI $98 5 payments
  9. INVEGA SUSTENNA $92 4 payments
  10. ABILIFY MAINTENA $88 5 payments
  11. Other $347 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

83

Median for Psychiatry: 574

Drug cost

$648

Median for Psychiatry: $27,624

Branded share of claims

0%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mirtazapine Generic 24 $256
Escitalopram Oxalate Generic 31 $162
Quetiapine Fumarate Generic 16 $149
Trazodone Hcl Generic 12 $82

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $75
$75 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $28
$28 — —
SUBLOCADE
  • Indivior Inc. $28
$28 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

75 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record